Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium

David J. Ross, VA Godfree, Alison Cooper, J. Pryse‐Davies, Malcolm Whitehead
In: Maturitas · 1997 · vol. 28(1) , pp. 83–88 · doi:10.1016/s0378-5122(97)00058-3 · PMID:9391999 · W2143643337
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

ObjectiveTo study the effects of oral trimegestone on endometrial histology and vaginal bleeding when given in combination with oral 17-beta-oestradiol.MethodsThis was a prospective, randomised, double-blind, parallel groups, pilot comparative study. Thirty-eight healthy postmenopausal women with normal endometrial histology were given oral 17-beta-oestradiol, 2 mg/day for three continuous cycles of 28 days, plus oral trimegestone, 0.10, 0.25 or 0.50 mg/day from day 15 to day 28 of each cycle. A Vabra biopsy was performed late in the oestradiol/trimegestone phase of cycle 3 and examined for histological evidence of secretory transformation of the endometrium. Characteristics of vaginal bleeding were recorded on a daily basis.ResultsThirty-seven women completed the study, of whom 31 yielded adequate tissue for histological assessment. All showed secretory transformation of the endometrium. Bleeding was of earlier onset and longer duration with the lowest dose of trimegestone.ConclusionsTrimegestone is a highly effective oral progestogen for endometrial protection, all doses inducing secretory endometrial transformation. Although bleeding patterns suggest a weaker effect of the lowest dose used, the minimum effective dose for endometrial protection has still to be determined and may be lower than those used in this study.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (15)

Source provenance

openalex
last seen: 2026-05-11T05:37:28.352103+00:00
License: CC0 · commercial use OK